酒精性肝硬化的中医证候特点研究
|
摘要
中医药在防治酒精性肝病方面具有潜在的优势和鲜明的特点,本课题旨在中医理论指导下,运用临床流行病学的方法和原则,从中医四诊角度对酒精性肝硬化的临床症状进行证候学分类,探讨酒精性肝硬化的中医证候特点,并以此归纳现阶段酒精性肝硬化在中医病名、证型上的分布,以达到为临床诊断及治疗起到一定的支持作用,为进一步的分析性研究和试验性研究奠定基础。本研究二部分组成:
理论研究部分,一部分内容总结了中医对酒精性肝病病因病机的认识,对当前国内有关中药方剂和有效成分治疗酒精性肝病以及酒精性肝病流行病学的研究进展进行了综述;另一部分系统论述了酒精性肝病现代理论研究及其临床治疗成果。
临床研究部分,为多中心前瞻性研究。以符合临床流行病学要求的全国5家医院病例资料为基础,对酒精性肝硬化患者的临床资料进行调查,探讨酒精性肝硬化患者中医证候分布的特点;应用熵聚堆统计分析方法,研究了120例酒精性肝硬化患者中医证候特点的分布以及发病特点。
研究结果:
实验一:男性为主要的饮酒和酒精性肝硬化患病人群;酒精性肝硬化的发病高峰年龄在50岁左右。不同职业人群酒精性肝硬化发生率有所不同,干部、商人最高,分别为29%和43%;日饮酒量160g/d,饮酒年限20年,累计酒精摄入量1500kg左右时,具有较高的患病率。酒精性肝硬化患者中谷氨酰转肽酶(γ-GT)值(100～250U/L)、AST/ALT比值＞2、碱性磷酸酶(ALP)值(220～550U/L)、总胆红素(TBIL)(34～51umol/1)、白蛋白(ALB)(28～35g/l)、凝血酶原百分活动度PTA(50%～70%)的出现率较高。
实验二:酒精性肝硬化患者中医证候特点为虚实夹杂;中医病位主要在肝胆脾肾;病机主要为气滞、血瘀、湿(热)浊内蕴,兼有肝肾阴虚,脾肾阳虚。证型主要分为:肝郁脾虚、脾虚湿盛、湿热内蕴、气滞血瘀、肝肾阴虚、脾肾阳虚。
Chinese medicine in the prevention and treatment of alcohol-induced liver disease has the potential advantages and distinctive features, TCM aims at the issue under the principle of theoretical guidance,the use of clinical epidemiology methods and principles,from the perspective of Chinese medicine clinic four to alcohol sclerosis clinical symptoms of the syndrome classification study to explore the alcohol-induced cirrhosis of the characteristics of TCM Syndrome,As summarized in alcoholic liver cirrhosis stage disease in Chinese medicine,evidence-based on the distribution,so as to achieve for the clinical diagnosis and treatment play a supporting role for the further analysis of the research and lay the foundation for pilot studies.In this study,two parts:
Theoretical study of the concluding part of traditional Chinese medicine on alcohol-induced liver disease etiology and pathogenesis of understanding on the current home of the active ingredients of Chinese medicine prescriptions and treatment of alcoholic liver disease alcoholic liver disease,as well as epidemiological Studies were reviewed;another part of the system on the modern theory of alcohol-induced liver cirrhosis and its clinical results.
Part of clinical research for the multi-center prospective study。To comply with the requirements of clinical epidemiology 5 national hospital-based clinical data on patients with alcoholic liver cirrhosis to investigate clinical data to explore traditional Chinese medicine in patients with alcoholic cirrhosis of the characteristics of Syndrome Distribution;application heap Poly entropy statistical analysis, studied 120 cases of alcoholic cirrhosis in patients with the characteristics of TCM Syndrome distribution,the characteristics of the incidence.
Study Results:
1:men as the main drinking and the prevalence of alcohol-induced liver cirrhosis group;alcoholic cirrhosis the peak age of incidence around the age of 50.Different occupational groups the incidence of alcoholic cirrhosis is different cadres,businessmen highest 29%and 43%;Alcohol day 160g / d,drinking age 20 years,cumulative alcohol intake of around 1500kg,has a high prevalence rate.Patients with alcoholic liver cirrhosis glutamyltranspeptidase enzyme(γ-GT) values (100 ~ 250U / L),AST / ALT ratio> 2,alkaline phosphatase(ALP) values (220 ~ 550U / L),total bilirubfn(TBIL)(34 ~ 51umol / 1),albumin(ALB) (25 ~ 31g / 1),percentage of prothrombin activity PTA(50%~ 70%) the emergence of a higher rate.
2:The TCM syndromes' feature of the ALC patients is the inclusion of excess and deficiency,In the TCM theory,ALC is mainly located at liver,gallbladder,spleen and kidney.Pathogenesis are qi-stagnancy and blood stasis,dampness and turbid things inside,besides yin deficiency of liver and spleen,yang vacuity of spleen and kidney.Syndromes include stagnation of liver-QI with deficiency of the spleen damp abundance,qi-stagnancy and blood stasis and hepatic and renal yin deficiency,asdthenic splenonephro-yang.
理论研究部分,一部分内容总结了中医对酒精性肝病病因病机的认识,对当前国内有关中药方剂和有效成分治疗酒精性肝病以及酒精性肝病流行病学的研究进展进行了综述;另一部分系统论述了酒精性肝病现代理论研究及其临床治疗成果。
临床研究部分,为多中心前瞻性研究。以符合临床流行病学要求的全国5家医院病例资料为基础,对酒精性肝硬化患者的临床资料进行调查,探讨酒精性肝硬化患者中医证候分布的特点;应用熵聚堆统计分析方法,研究了120例酒精性肝硬化患者中医证候特点的分布以及发病特点。
研究结果:
实验一:男性为主要的饮酒和酒精性肝硬化患病人群;酒精性肝硬化的发病高峰年龄在50岁左右。不同职业人群酒精性肝硬化发生率有所不同,干部、商人最高,分别为29%和43%;日饮酒量160g/d,饮酒年限20年,累计酒精摄入量1500kg左右时,具有较高的患病率。酒精性肝硬化患者中谷氨酰转肽酶(γ-GT)值(100～250U/L)、AST/ALT比值＞2、碱性磷酸酶(ALP)值(220～550U/L)、总胆红素(TBIL)(34～51umol/1)、白蛋白(ALB)(28～35g/l)、凝血酶原百分活动度PTA(50%～70%)的出现率较高。
实验二:酒精性肝硬化患者中医证候特点为虚实夹杂;中医病位主要在肝胆脾肾;病机主要为气滞、血瘀、湿(热)浊内蕴,兼有肝肾阴虚,脾肾阳虚。证型主要分为:肝郁脾虚、脾虚湿盛、湿热内蕴、气滞血瘀、肝肾阴虚、脾肾阳虚。
Chinese medicine in the prevention and treatment of alcohol-induced liver disease has the potential advantages and distinctive features, TCM aims at the issue under the principle of theoretical guidance,the use of clinical epidemiology methods and principles,from the perspective of Chinese medicine clinic four to alcohol sclerosis clinical symptoms of the syndrome classification study to explore the alcohol-induced cirrhosis of the characteristics of TCM Syndrome,As summarized in alcoholic liver cirrhosis stage disease in Chinese medicine,evidence-based on the distribution,so as to achieve for the clinical diagnosis and treatment play a supporting role for the further analysis of the research and lay the foundation for pilot studies.In this study,two parts:
Theoretical study of the concluding part of traditional Chinese medicine on alcohol-induced liver disease etiology and pathogenesis of understanding on the current home of the active ingredients of Chinese medicine prescriptions and treatment of alcoholic liver disease alcoholic liver disease,as well as epidemiological Studies were reviewed;another part of the system on the modern theory of alcohol-induced liver cirrhosis and its clinical results.
Part of clinical research for the multi-center prospective study。To comply with the requirements of clinical epidemiology 5 national hospital-based clinical data on patients with alcoholic liver cirrhosis to investigate clinical data to explore traditional Chinese medicine in patients with alcoholic cirrhosis of the characteristics of Syndrome Distribution;application heap Poly entropy statistical analysis, studied 120 cases of alcoholic cirrhosis in patients with the characteristics of TCM Syndrome distribution,the characteristics of the incidence.
Study Results:
1:men as the main drinking and the prevalence of alcohol-induced liver cirrhosis group;alcoholic cirrhosis the peak age of incidence around the age of 50.Different occupational groups the incidence of alcoholic cirrhosis is different cadres,businessmen highest 29%and 43%;Alcohol day 160g / d,drinking age 20 years,cumulative alcohol intake of around 1500kg,has a high prevalence rate.Patients with alcoholic liver cirrhosis glutamyltranspeptidase enzyme(γ-GT) values (100 ~ 250U / L),AST / ALT ratio> 2,alkaline phosphatase(ALP) values (220 ~ 550U / L),total bilirubfn(TBIL)(34 ~ 51umol / 1),albumin(ALB) (25 ~ 31g / 1),percentage of prothrombin activity PTA(50%~ 70%) the emergence of a higher rate.
2:The TCM syndromes' feature of the ALC patients is the inclusion of excess and deficiency,In the TCM theory,ALC is mainly located at liver,gallbladder,spleen and kidney.Pathogenesis are qi-stagnancy and blood stasis,dampness and turbid things inside,besides yin deficiency of liver and spleen,yang vacuity of spleen and kidney.Syndromes include stagnation of liver-QI with deficiency of the spleen damp abundance,qi-stagnancy and blood stasis and hepatic and renal yin deficiency,asdthenic splenonephro-yang.
引文
[1]金容炫,张浩,田德禄.田德禄教授治疗酒精性肝损伤的临床经验[J].中国中医基础医学杂志,2003,9(8):66-67.
[2]张明雪.酒精性肝损伤的中医证治与微观化研究[J].辽宁中医杂志,1996,23(7):299.
[3]王天舒,刘文康,刘传方.解酒保肝汤治疗酒精性脂肪肝临床观察[J].中国中西医结合杂志,1995,15(7):439.
[4]赵益梅,韩涛,于学美.试从血瘀论酒精性肝损伤[J].吉林中医药,2004,24(9):1.
[5]丁霞,田德禄,姚雪彪,中医学对酒精性肝纤维化的认识,中华中医药杂志,2006;21(1):50-53.
[6]牛建昭,李健等。酒精性肝纤维化“毒损肝络”病机假说的形成及临床意义。中西医结合肝病杂志,2007;(1):17-18.
[7]周滔,刘坚.解酲冲剂治疗慢性酒精性肝损伤30例[J].中西医结合肝病杂志,2002,129(3):181.
[8]崔剑平.温胆汤加味治疗酒精性肝损伤38例[J].时针国医国药,2006,17(7):1278.
[9]胡福田.黄连温胆汤加减治疗酒精性肝损伤43例疗效观察[J].药物与临床,2005,2(11):77.
[10]桑得友,李承远,刘桂芬.甘露消毒丹治疗酒精性肝损伤[J].湖北中医杂志,2000,22(11):31.
[11]孙刚,刘铁军,邓厚波.甘露消毒丹加减治疗慢性肝病附加酒精性肝损伤临床观察[J].吉林中医药,2006,26(5):18.
[12]越口荣信.酒精性肝炎、肝功能损伤及其合并症的东洋医学诊断、治疗和并用西药疗法[J].日本东洋医学杂志,1985,36(2):27
[13]彬木利一朗.慢性酒精性肝损害的随证治疗[J].日本东洋医学杂志,1995,45(5):188.
[14]太田好次.八味地黄丸的临床与实验药理研究[J].于建军,耿杰译.国外医学·中医中药分册,1999,21(5):328
[15]高四昭.酒精性肝损害、脂肪肝与汉方[J].杨普翔译.国外医学·中医中药分册,1988,10(6):628
[16]张显耀.强肝再生丸治辽酒精性肝损伤63例疗效观察[J].浙江中医学院学报,2000,24(5):42.
[17]杜景海.化痰活血汤治疗酒精性肝损伤临床观察[J].中华中医药学刊,2007,25(4):854.
[18]许亦斌,季光.清肝活血方防治酒精性肝损伤的临床研究[J].江苏中医药,2003,24(9):18.
[19]王天舒,刘文康,刘传方.解酒保肝汤治疗酒精性脂肪肝临床观察[J].中国中西医结合杂志,1995,15(7):439.
[20]田德禄,姚素珍.中药慢肝消治疗酒精性肝损伤的临床研究[J].华人消化杂志,1998,6(11):945.
[21]祁培宏.酒肝胶囊治疗酒精性肝损伤的临床研究[J].时珍国医国药,2007,18(5):1206.
[22]王哲,郭宏华,陈宇,等.血脂康治疗酒精性肝病的临床观察[J].中国老年学杂志,2000;20(3):160-161.
[23]钱海清.清热凉血解酒汤治疗酒精性肝病67例[J].浙江中西医结合杂志,2000;10(3):491-492.
[24]陈玉,赵俊精等人.清肝饮对大鼠酒精性肝病的防治研究[J].中国中医药科技.2008;15(6):424-425.
[25]贾庆宇.曲灵双葛汤治疗酒精性肝病的临床研究.医学理论与实践[J],2008;21(9):1014-1015.
[26]丁霞,田德禄,焉小丽,等.调肝理脾方治疗酒精性肝纤维化的临床研究[J].北京中医药大学学报,2000;23(3):58-61.
[27]潘永峰,李凤皖.清开灵加黄茂治疗酒精性肝病的疗效分析[J].肝脏,2001;6(2):141-142.
[28]桑德友,李承远,刘桂芬.甘露消毒丹治疗酒精性肝病临床研究[J].湖北中医杂志,2000:22(11):31.
[29]俞志高.酒肝丸胶囊治疗酒精性肝病16例[J].浙江中医杂志,2001;(11):469.
[30]陈德永,杨永平.复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化Ⅱ期临床试验总结[J].传染病信息,1999,12(2):61-62.
[31]高广甫,杨萱.复方鳖甲软肝片治疗肝纤维化临床研究[J].临床肝胆病杂志,2005,21(6):375-376.
[32]吴春晓,陈燕鸿.复方鳖甲软肝片治疗肝纤维化疗效探讨.山东医药,2006,46(23):55
[33]曲鹏,杨子洋,王彦君.复方鳖甲软肝片治疗肝纤维化42例疗效观察.ChineseGeneral Practice,2004,17(120):1526-1527
[34]龚启明,肖家诚,周霞秋.复方鳖甲软肝片治疗50例肝纤维化的临床研究[J].Chin JClini Hepatol,2006,122(13):196-198.
[35]宁小艳,唐蒙轩,陈星浩,等.复方鳖甲软肝片与和络舒肝胶囊治疗肝纤维化疗效比较[J].华北煤炭医学院学报,2006,8(3):341-342.
[36]赵景民,周光德,李文淑,等.复方鳖甲软肝片抗肝纤维化机制的实验研究[J].解放军医学杂志,2004,29(7):560-562.
[37]周光德,李文淑,赵景民,等.复方鳖甲软肝片抗肝纤维化机制的临床病理研究[J].解放军医学杂志,2004,29(7):563-564.
[38]陈利坚,叶淑芳.复方鳖甲软肝片合C-干扰素治疗肝炎后肝纤维化.浙江中西医结合杂志,2005,15(10):595-596.
[39]杨牧祥,李荣彦,田元祥,等.解酒护肝饮治疗酒精性肝病的临床疗效观察[J].中国中医药信息杂志,2001,8(1):59-60.
[40]乔作现.中药治疗酒精性肝病42例[J].河南中医,2003,23(3):18-19.
[41]王育群,季光,张玮,等.清肝活血方治疗酒精性肝病的随机对照临床研究[J].北京中医杂志,2002,21(4):195-198.
[42]许亦斌,季光.“清肝活血方”防治酒精性肝病的临床研究.江苏中医药[J],2003,24(9):18-21.
[43]季光.清肝活血方治疗酒精性肝病的临床研究[J].中西医结合学报,2003,1(2):103-108.
[44]林爱清,李文彪,张瑞芬等.清源调脂胶囊治疗酒精性肝病临床效果评价[J].中西医结合肝病杂志,2006,16(1):11-13.
[45]李文彪,王毅仁.清源调脂胶囊治疗高脂血症性脂肪肝实验研究[J].中西医结合肝病杂志,2001,11(3):159-161.
[46]沈映君主编.中药药理学.北京:人民卫生出版社,2000.4.18
[47]何炜.解酒清肝汤治疗酒精性肝病46例[J].陕西中医,2006,26(9):1074-1075.
[48]郭晓萍,程宇甫,袁勤钊,等.加味四逆散治疗酒精性肝病临床研究[J].中国中医药信息杂志,2006,13(6):13-14.
[49]郭晓萍,程宇甫,袁勤钊,等.加味四逆散防治大鼠酒精性肝病实验研究[J].中国中医药信息杂志,2006,13(5):33-34.
[50]许亦斌,季光.清肝活血方防治酒精性肝损伤的临床研究[J].江苏中医药,2003,24(9):18.
[51]何炜.解酒清肝汤治疗酒精性肝损伤46例[J].陕西中医,2006,26(9):1074.
[52]白静丽,杨世忠.肝脂溶颗粒治疗酒精性肝损伤的临床研究[J].中国社区医师,2005,7(23):24.
[53]杜景海.化痰活血汤治疗酒精性肝损伤临床观察[J].中华中医药学刊,2007,25(4):854.
[54]杨牧祥,李荣彦等.解酒护肝饮治疗酒精性肝损伤的临床疗效观察[J].中国中医药信息杂志,2001,8(1):59.
[55]付月箫等.消脂护肝汤治疗酒精性肝损伤93例临床研究[J].新中医,2007,39(11):72.
[56]郭晓萍,程宇甫.加味四逆散治疗酒精性肝损伤临床研究[J].中国中医药信息杂志,2006,13(6):13.
[57]苗士奎等.脂肝康胶囊治疗酒精性肝损伤的研究[J].中西医结合肝病杂志,2005,15(5):266.
[58]喻洪伟,张春梅.酒肝乐治疗酒精性肝损伤疗效观察[J].辽宁中医杂志,2003,30(14):284.
[59]倪力强,周学文.卷苦肝泰治疗酒精性肝损伤得临床研究[J].辽宁中医杂志,2003,30(5):343.
[60]王芳.清肝解毒汤治疗酒精性肝损伤r-GT升高的体会[J].浙江中医学院学报,2001,25(2):40.
[61]任延明,任世存等.八味护肝胶囊治疗酒精性肝损伤42例临床观察[J].江苏中医药,2004,25(9):25。
[62]沙美,丁林生.枳椇子的化学成分研究.中国药科大学学报 2001,32(6):418-420。
[63]嵇扬,李俊,杨平.枳椇子对急性酒清中毒的作用[J].中药材,2001,24(2):126-128。
[64][英]HaseK...和汉医药学杂志[J].1997,14(1):28-33
[65]嵇扬,杨平,李俊.枳椇子酒与枳棋子水提取液解酒毒作用比较研究[J].时珍国医国药,2001,12(6):481-483
[66]Yoshikawa M,Murakami T,Ueda T,et al.Bioactive constituents of Chinesenatural medicines Ⅱ Absolite stereostructures of new di-hydroflavonols,hoveninitins Ⅰ,ⅡandⅢ,isolated from hoveniae semen fructu,the seed and fruid of Hoveniadulcis THUNB.(Rhamnaceae):inhibitory effect on alcohol-induced muscure laxation and hepatoprotective activity[J].Yakugaku Zasshi,1997,117
[67]张洁、刘庆生等。三七对酒精性肝病防治作用的研究[J]。医学研究杂志,2008;37(3):35-36.
[68]范列英,孔涛,高峰,等.汉防己甲素对成纤维细胞、肝细胞DNA及胶原合成的影响[J].临床肝胆病杂志,1995;11(1):25-26.
[69]刘玉兰,李定国,陆汉明,等.汉防己甲素对肝细胞及成纤维细胞的影响[J].中西医结合肝病杂志,1994;4(4):21-23.
[70]李定国,刘玉兰,陆汉明,等.汉防己甲素对肝纤维化大鼠线粒体的影响[J].中华消化杂志.1994;16(4):339.
[71]王志荣,李定国,魏红山,等.粉防己碱抑制肝纤维化大鼠肝组织c-fos 和c-junmRNA表达[J].上海医学,2003;26(5):332-334.
[72]靖大道,邱德凯,萧树东,等.虫草多糖(CP)对大鼠肝细胞增殖及胶原基因表达的影响[J].肝脏,1999;4(4):215-216.
[73]朱家璇.冬虫夏草对实验性免疫损伤性肝纤维化的预防和治疗作用研究.中华消化杂志,1994;14(6):333.
[74]邱德凯,李海,曾民德,等.虫草多糖对大鼠肝纤维化胶原酶mRNA变化的 影响[J].新消化学杂志,1997;5(7):417-419.
[75]薛惠明,胡义杨,顾宏图,等.丹参抗CC14及DMN诱导的大鼠肝纤维化的研究[J].中西医结合肝病杂志,1999;9(4):16-17.
[76]马学惠,等.丹参对实验性肝硬化细胞外基质影响的免疫组化观察[J].肝脏病杂志,1994;2(2):79.
[77]王晓玲,刘平,刘成海,等.丹酚酸A对成纤维细胞活力增殖及胶原合成的影响[J].中西医结合肝病杂志,2000;10(1):24-25.
[78]刘丽,姜慧卿,张晓凤.丹参单体IH764-3对H2O2刺激肝星状细胞增殖和胶原合成的影响及其机制[J].中国应用生理学杂志,2003;19(1):78-81.
[79]甘乐文,等.氧化苦参碱对大鼠肝纤维化的影响第二军医大学学报,1999,20(7):445-448.
[80]林明华,马迎军,孟庆援,等.苦参素对肝星状细胞增殖及Ⅰ型胶原合成的影响.黑龙江医药科学,2003,26(1):27-28.
[81]康文臻.苦参素对实验性大鼠肝纤维化防治作用的研究[J].世界华人消化杂志,2003;11(2):195-198.
[82]张珉.黄颜木素对HSC-T6细胞增殖和胶原合成的影晌.第二军医大学学报,1999,20(5):304-305.
[83]夏玉涛,卫新革,陈颖伟,等.大黄素对肝纤维化大鼠血清透明质酸的影响[J].中西医结合肝病杂志,1999,9(4):27.
[84]张霄翔,扬雁,陈敏珠.黄芪多糖对HSC-T6细胞增殖及胶原产生的影响[J].中国临床药理学与治疗学,2003;8(6):645-647.
[85]吴强,杨雁,薛绍礼,等.黄芪总甙对肝星状细胞增殖和合成胶原的抑制作用[J].中国药理学通报,2003;19(8):892-895.
[86]胡梅雪.活血化瘀法治疗肝纤维化[J].中医药学报,1998;5(2):13.
[87]赵治友,何永生.慢性肝炎从瘀论治探析[J].中医药学报,1998;5(6):15.
[88]徐萃华,李燕娜.赤芍对体外培养肝细胞(甲基-3H)胸腺嘧啶核苷掺入的影响[J].山西医药杂志,1986;(5):299-232.
[89]李绥军,林玲,王莉.活血清肝汤配合易善复治疗酒精性肝炎45例.陕西中医,2005;26;(1):7-9.
[90]涂立德.硫普罗宁、复方丹参治疗酒精性肝炎40例.赣南医学院学报,2007;27(3):419-420.
[91]阎振文.中西医结合治疗酒精性肝炎30例.中国民间疗法,2007,15(4):4-5.
[92]张洁玉.调肝活血方抗酒精性肝病的临床观察.中医药学报,2007;35(3):56-57.
[1].中华医学会肝病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊标准.中华肝脏病杂志,2003,112):72.
[2].Donofrio G,Bernstein E,Bernatein J,Woolare RH,Brewer PA,Craig SA,Zink BJ,Patients with alcohol problems in the emergency department part1:improving dection.SAEM substance Abuse Task Force.Society for Academeic Emergency Medicine.Acad Emerg Med,1998,5:1200-1209.
[3].Sussman S,Denl VW,Skara S,de Calice P,Tsukamoto H.Alcoholic liver disease(ALD):a new domain for prevention efforts.Subst Use Misuse,2002,37:1887-1904.
[4].Ramstendt M.Alocohol related mortanty in 15 European countries in the post war period,http://www-les-lundis,ined fr/cextes/MatsRamstedt.pdf.
[5].Neuberger J,SchulzKH,DayC,Fleig W,BerlakovichGA,Berenguer M,Pageaux GP,Luccy M,Horsmans Y,Burroughs A,Hockeratedt K.Transplantation for alcoholic liver disease.J Hepatol,2002,36:130-137.
[6].王宝恩,尹珊珊.酒精性肝病的流行病学.中华肝脏病杂志[J],2001;9:312.
[7].凌奇荷,卿笃信.重视对酒精性肝病的研究[J].中华消化杂志,2001,21:517-518.
[8].厉有名,陈卫星,虞朝辉,等.浙江省酒精性肝病流行病学调查概况[J].中华肝脏病杂志,2003,11 11):647-649.
[9].王宏平.88例酒精性肝病的临床分析[J].中外健康文摘·医药学刊,2008,5(1):7-8.
[10].王国祥,王炳元,刘春荣.肝胃乙醇脱氢酶活性与酒精性肝病方式的关系[J].中华肝脏病杂志,2001,9(5):265-267.
[11].Bode CH,Bode,JC.Effect of a;coho;consumption on the gut.Best Practice & Reseach Clinical Gastroenterology,2003,17:574-592.
[12].Niemela O.Distribution of ethanol-induced protain in vivo:relationship to tissue injury in CD14-difcient mice.J Immunol,2001,31:1533-1538.
[13].黄梅芳,酒精性肝病的发病机制的研究进展[J],医学新知杂志 2003,13(2):104-108。
[14].周俊英.缺氧诱导因子-1与酒精性肝病[J].国际内科学杂志.2008;35(9):544-545.
[15].Gordon H.Detection of alcoholic liver disease.World J Gastroencerol,2001,7:297-302.
[16].Bellentani S,Saccoecio G,Costa G,Tiribelli C,Manenti F,Sodde M,Saveria Croce L,Sasso F,Pozzato G,Cristianini G,Brandi G.Drinking habits as cofactors of risk for alcohol induced liver damage.The Dionysos Study Group.Gut,1997,41:845-850.
[17].鲁晓岚,陶明,罗金燕等.饮酒与肝病流行病学调查[J].中华肝脏病杂志,2002,10:467-468.
[18].Morgan MY,Sherlock S.Sxe-related differences among 100 patients with alcoholicliver disease.Br Med J,1977;5:1939-1941.
[19].Casini A.Acetaldehyde induces clos and cjun drotooncogenes in fat-storing cellcultures through protein kinase C activation.Alcohol,1994;29:303-313
[20].Westin J,Lagging LM,Spak F,Aires N,Svensson E,Lindh M,Dhillon AP,Norkrans G,WejstalR.Moderatoalcoholinstake increasesfibrosisprogression in untreated pationts with hepatitis C virus infection.J Viral Hepat,2002,9:235-241.
[21].Bunout D.Nutritional and metabolic effects of alcoholism:their relationship with alcoholic liver disease.Nutrition.1999,15:583-589.
[22].中华医学会肝病学分会脂肪肝和酒精性肝病学组,酒精性脂肪性肝病诊断标准[J],中华肝脏病杂志2006,3,14,3.164-166.
[23].中华医学会肝病学分会脂肪肝和酒精性肝病学组,酒精性脂肪肝性肝病诊断标准[J],中华肝脏病杂志 2003,11:72.
[24].Sanyal AJ.AGA technical review on nonalcoholic fatty liver disease.Gastroenterology 2002;123:1705-1725.
[25].Graif M,Yanuka M,Baraz M,et al.Quantitative estimation of attenuation in ultrasound video images:correlation with histology in diffuse liver disease.Invest Radiol 2000;35:319-324.
[26].Ataseven H,Yildrim MH,Yalniz M,et al.Correlation between computerized tomographic findings and histopathologic grade/stage innon-alcoholic steatohepatitis.J Hepatol 2003;38(Suppl 2):A4177.
[27].Farrell GC,George J,Pauline MH,McCullough AJ,eds.Fatty liver diseas:NASH and related disorders.Oxford:Blackwell Publishing 2005:159-207.
[28].桂红莲,谢青.肝纤维化无创性诊断的研究进展.内科理论与实践[J], 2007,2(25):360-363.周新,涂植光.临床生物化学和生物化学检验.人民卫生出版社.2003,167-168.
[29].周新,涂植光.临床生物化学和生物化学检验[J].人民卫生出版社.2003,167-168.
[30].叶彬,潘发愤.酒精性脂肪肝和肝硬化患者各种血清酶的检测及其临床评价[J].浙江临床医学,2006,8(12):1252-1253.
[31].詹雨林,李国航,骆欢.慢性肝病血清γ-谷氨酰转移转酶测定的临床意义[J].中国实用医药,2007,2 25):42-43.
[32].朱一堂,孙艳,李福坤,等.血清亮氨酸氨基肽酶和γ-谷氨酰转肽酶在酒精性肝病诊断中的应用[J].国际检验医学杂志,2006,2712):1146-1147.
[33].陆伦根.肝纤维化非创伤性诊断的临床应用[J].中华肝脏病杂志,2007,15:777-778.
[34].孟繁坤,丁蕾,郑颖,等.超声判别慢性肝病肝纤维化分期与病理背离问题探讨[J].临床超声医学杂志,2007,9:394-397.
[35].孟繁坤,郑颖,葛辉玉,等.高频超声检查与病理肝纤维化分期相关性的半定量研究[J].中国超声医学杂志,2007,23(11):846-848.
[36].McCullough AJ,O′ Connor JF.Alcoholic liver disease:proposed recommendations for the American College of Gastroenterology.Am J Gastroenterol 1998;93:2022-2036.
[37].Sticke1 F,Roehn B,Schuppan D,et at.Review article:Nutritional therapy in alcoholic liver disease.Aliment Pharmacol Ther 2003;18:357-373.
[38].Mathurin P,Mendenhall CL,Carithers RL Jr,et al.Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis(AH):individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH.JHepatol 2002;36:480-487.
[39].Imperiale TF,O′Connor JB,McCullough AJ.Corticosteroids are effective in patients with severe alcoholic hepatitis.Am J Gastroenterol 1999;94:3066-3068.
[40].Shpilenya LS,Muzychenko AP,Gasbarrini G,et al.Metadoxine in acute alcohol intoxication:a double-blind,randomized,place bocontrolled study.Alcohol Clin Exp Res 2002;26:340-346.
[41].Medina J,Moreno-Otero R.Pathophysiological basis for antioxidant therapy in chronic liver disease.Drugs 2005;65:2445-2461.
[42].胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏2005;10:5-7.
[43].Lieber CS,Leo MA,Cao Q,et al.Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons.J Clin Gastroenterol 2003;37:336-339.
[44].Murray KF,Carithers RL Jr;AASLD.AASLD practice guidelines Evaluation of t the patient for liver transplantation.Hepatology 2005;41:1407-1432.
[45].黄飚.23例酒精性肝硬化诊治分析.医学理论与实践[J],2008,21(6):679-680.
[46].Stickel F,Hoehn B,Schuppan D,et al.Review article:Nutritional therapy in alcoholic liver disease.Aliment Pharmacol Ther 2003;18:357-373.
[47].MendenhallCL,ToschT,WeesnerRE,etal.Vacooperative study on Alcoholic hepatitis.Ⅱ.Prognostic significance of protein 2calorie malnutrition[J].Am J Clin Nutr,1986;43:213-221.
[48].Rambaldi A,Gluud C.Anabolic-androgenic steroids for alcoholic liverdisease[J].Cochrane Database Syst Rev,2006,(4):CD003045.
[49].王宛明,王道存.多烯磷脂酰胆碱治疗酒精性肝病疗效观察[J].现代中西医结合杂志.2008,17(25):3941-3942.
[50].Lieber CS.New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments[J].Curr Gastroenterol Rep,2004,6:60-65.
[51].Lieber CS.Liver diseases by alcohol and hepatitis C:early detection and new insights in pathogenesis lead to improved treatment[J].Am J Addict,2001,10(Suppl):29-50.
[52].Mookerjee Rp,Tilg H,Williams R,etal.Infliximab and alcoholic hepatitis[J].Hepatology,2004,40:499-500.
[53].万远太.酒精性肝病的药物治疗现状[J].武汉科技大学学报(自然科学版),2006,29(2):194-196.
[54].范建高,曾民德.脂肪性肝病[M].北京:人民卫生出版社,2005:366-410.。
[3]Levitsky J,Mailliard ME.D iagnosis and therapy of alcoholic liv2er disease[J].Sem in Liver D is,2004,24:233-247.
[55].Neuber ger J,Schulz KH,Day C,etal.Transplantation for alcoholic liver disease[J].Hepatol,2002;36:130-137.
[56].Friedman SL.Liver fibrosis-fran bench to beside.J.J Hepatology,2003,38:S38-S53.
[1]庄辉.酒精性肝病的流行病学[J].中华肝脏病杂志,2003;11(11):689
[2]O' Keefee C,McCormick PA.Severe acute alcoholic hepatitis:an audit of medical treatment.Ir Med J 2002;95:108-109
[3]Campollo O,,Martinez MD,Valencia JJ,Segura-Ortega J.Drinking patterns and beverage preferences of liver cirrhosis patients in Mexico.Subst Use Misuse 2001;36:387-398
[5]Bopp M,Gmel G.Alcohol consumption and gender in the 20th century:the case of Switzerland.Soz Praventivmed 1999;44:211-221
[4]Campollo O,Martinez MD,Valencia JJ,Segura-Ortega J.Drinking patterns and beverage preferences of liver cirrhosis patients in Mexico.Subst Use Misuse 2001;36:387-398
[5]江正辉,王泰龄.酒精性肝病[J],中国医药科技出版社,2001;116
[6]Campollo O,,Martinez MD,Valencia JJ,Segura-Ortega J.Drinking patterns and beverage preferences of liver cirrhosis patients in Mexico.Subst Use Misuse 2001;36:387-398
[7]酒精性肝病诊断标准(草案)[J].中华肝脏病杂志,2001,9(5):264
[8]Cotton NS.The familial incidence of alcoholism:a review.J Stud Alcohol 1979;40:89-116
[9]Gordon H.Detection of alcoholic liver disease.World J Gastroenterol 2001,7:297-302。
[10]陈卫星.酒精性肝病流行病学调查和危险因素分析[J].博士论文.2001,5(1):15-16
[11]Gordon H.Detection of alcoholic liver disease.World J Gastroenterol 2001:7:297-302
[12]Grant BF,Noble J,Malin H.Dcclinein liver irrhosis mortality and components of change:United States,1973-1983.AIcohol Health and Research World,1980,10:66-75
[13]Sorbi D,Boynton J,Lindor KD.The ratio of aspartate aminotransferase toalanine aminotransferase potential value in differentiating nonalcoholicsteatohepatitis from alocoholic liver disease.Am J Gastroenterol,1999,94:1018-1022
[14]张道明,王远新,赵洪川,等.酒精性肝病-附136例临床与病理[J].胃肠病学和肝病学杂志.1996,5(3):196-201
[1]袁世宏,张连文,王米渠.数理统计思想及方法在辨证规范化研究中的应用及思考.中国中医基础医学杂志,2003;9(4):15-19。
[2]陈平雁,黄淅明.SPSS10.0统计软件应用教程.人民军医出版社,2002:198-199.
[2]张明雪.酒精性肝损伤的中医证治与微观化研究[J].辽宁中医杂志,1996,23(7):299.
[3]王天舒,刘文康,刘传方.解酒保肝汤治疗酒精性脂肪肝临床观察[J].中国中西医结合杂志,1995,15(7):439.
[4]赵益梅,韩涛,于学美.试从血瘀论酒精性肝损伤[J].吉林中医药,2004,24(9):1.
[5]丁霞,田德禄,姚雪彪,中医学对酒精性肝纤维化的认识,中华中医药杂志,2006;21(1):50-53.
[6]牛建昭,李健等。酒精性肝纤维化“毒损肝络”病机假说的形成及临床意义。中西医结合肝病杂志,2007;(1):17-18.
[7]周滔,刘坚.解酲冲剂治疗慢性酒精性肝损伤30例[J].中西医结合肝病杂志,2002,129(3):181.
[8]崔剑平.温胆汤加味治疗酒精性肝损伤38例[J].时针国医国药,2006,17(7):1278.
[9]胡福田.黄连温胆汤加减治疗酒精性肝损伤43例疗效观察[J].药物与临床,2005,2(11):77.
[10]桑得友,李承远,刘桂芬.甘露消毒丹治疗酒精性肝损伤[J].湖北中医杂志,2000,22(11):31.
[11]孙刚,刘铁军,邓厚波.甘露消毒丹加减治疗慢性肝病附加酒精性肝损伤临床观察[J].吉林中医药,2006,26(5):18.
[12]越口荣信.酒精性肝炎、肝功能损伤及其合并症的东洋医学诊断、治疗和并用西药疗法[J].日本东洋医学杂志,1985,36(2):27
[13]彬木利一朗.慢性酒精性肝损害的随证治疗[J].日本东洋医学杂志,1995,45(5):188.
[14]太田好次.八味地黄丸的临床与实验药理研究[J].于建军,耿杰译.国外医学·中医中药分册,1999,21(5):328
[15]高四昭.酒精性肝损害、脂肪肝与汉方[J].杨普翔译.国外医学·中医中药分册,1988,10(6):628
[16]张显耀.强肝再生丸治辽酒精性肝损伤63例疗效观察[J].浙江中医学院学报,2000,24(5):42.
[17]杜景海.化痰活血汤治疗酒精性肝损伤临床观察[J].中华中医药学刊,2007,25(4):854.
[18]许亦斌,季光.清肝活血方防治酒精性肝损伤的临床研究[J].江苏中医药,2003,24(9):18.
[19]王天舒,刘文康,刘传方.解酒保肝汤治疗酒精性脂肪肝临床观察[J].中国中西医结合杂志,1995,15(7):439.
[20]田德禄,姚素珍.中药慢肝消治疗酒精性肝损伤的临床研究[J].华人消化杂志,1998,6(11):945.
[21]祁培宏.酒肝胶囊治疗酒精性肝损伤的临床研究[J].时珍国医国药,2007,18(5):1206.
[22]王哲,郭宏华,陈宇,等.血脂康治疗酒精性肝病的临床观察[J].中国老年学杂志,2000;20(3):160-161.
[23]钱海清.清热凉血解酒汤治疗酒精性肝病67例[J].浙江中西医结合杂志,2000;10(3):491-492.
[24]陈玉,赵俊精等人.清肝饮对大鼠酒精性肝病的防治研究[J].中国中医药科技.2008;15(6):424-425.
[25]贾庆宇.曲灵双葛汤治疗酒精性肝病的临床研究.医学理论与实践[J],2008;21(9):1014-1015.
[26]丁霞,田德禄,焉小丽,等.调肝理脾方治疗酒精性肝纤维化的临床研究[J].北京中医药大学学报,2000;23(3):58-61.
[27]潘永峰,李凤皖.清开灵加黄茂治疗酒精性肝病的疗效分析[J].肝脏,2001;6(2):141-142.
[28]桑德友,李承远,刘桂芬.甘露消毒丹治疗酒精性肝病临床研究[J].湖北中医杂志,2000:22(11):31.
[29]俞志高.酒肝丸胶囊治疗酒精性肝病16例[J].浙江中医杂志,2001;(11):469.
[30]陈德永,杨永平.复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化Ⅱ期临床试验总结[J].传染病信息,1999,12(2):61-62.
[31]高广甫,杨萱.复方鳖甲软肝片治疗肝纤维化临床研究[J].临床肝胆病杂志,2005,21(6):375-376.
[32]吴春晓,陈燕鸿.复方鳖甲软肝片治疗肝纤维化疗效探讨.山东医药,2006,46(23):55
[33]曲鹏,杨子洋,王彦君.复方鳖甲软肝片治疗肝纤维化42例疗效观察.ChineseGeneral Practice,2004,17(120):1526-1527
[34]龚启明,肖家诚,周霞秋.复方鳖甲软肝片治疗50例肝纤维化的临床研究[J].Chin JClini Hepatol,2006,122(13):196-198.
[35]宁小艳,唐蒙轩,陈星浩,等.复方鳖甲软肝片与和络舒肝胶囊治疗肝纤维化疗效比较[J].华北煤炭医学院学报,2006,8(3):341-342.
[36]赵景民,周光德,李文淑,等.复方鳖甲软肝片抗肝纤维化机制的实验研究[J].解放军医学杂志,2004,29(7):560-562.
[37]周光德,李文淑,赵景民,等.复方鳖甲软肝片抗肝纤维化机制的临床病理研究[J].解放军医学杂志,2004,29(7):563-564.
[38]陈利坚,叶淑芳.复方鳖甲软肝片合C-干扰素治疗肝炎后肝纤维化.浙江中西医结合杂志,2005,15(10):595-596.
[39]杨牧祥,李荣彦,田元祥,等.解酒护肝饮治疗酒精性肝病的临床疗效观察[J].中国中医药信息杂志,2001,8(1):59-60.
[40]乔作现.中药治疗酒精性肝病42例[J].河南中医,2003,23(3):18-19.
[41]王育群,季光,张玮,等.清肝活血方治疗酒精性肝病的随机对照临床研究[J].北京中医杂志,2002,21(4):195-198.
[42]许亦斌,季光.“清肝活血方”防治酒精性肝病的临床研究.江苏中医药[J],2003,24(9):18-21.
[43]季光.清肝活血方治疗酒精性肝病的临床研究[J].中西医结合学报,2003,1(2):103-108.
[44]林爱清,李文彪,张瑞芬等.清源调脂胶囊治疗酒精性肝病临床效果评价[J].中西医结合肝病杂志,2006,16(1):11-13.
[45]李文彪,王毅仁.清源调脂胶囊治疗高脂血症性脂肪肝实验研究[J].中西医结合肝病杂志,2001,11(3):159-161.
[46]沈映君主编.中药药理学.北京:人民卫生出版社,2000.4.18
[47]何炜.解酒清肝汤治疗酒精性肝病46例[J].陕西中医,2006,26(9):1074-1075.
[48]郭晓萍,程宇甫,袁勤钊,等.加味四逆散治疗酒精性肝病临床研究[J].中国中医药信息杂志,2006,13(6):13-14.
[49]郭晓萍,程宇甫,袁勤钊,等.加味四逆散防治大鼠酒精性肝病实验研究[J].中国中医药信息杂志,2006,13(5):33-34.
[50]许亦斌,季光.清肝活血方防治酒精性肝损伤的临床研究[J].江苏中医药,2003,24(9):18.
[51]何炜.解酒清肝汤治疗酒精性肝损伤46例[J].陕西中医,2006,26(9):1074.
[52]白静丽,杨世忠.肝脂溶颗粒治疗酒精性肝损伤的临床研究[J].中国社区医师,2005,7(23):24.
[53]杜景海.化痰活血汤治疗酒精性肝损伤临床观察[J].中华中医药学刊,2007,25(4):854.
[54]杨牧祥,李荣彦等.解酒护肝饮治疗酒精性肝损伤的临床疗效观察[J].中国中医药信息杂志,2001,8(1):59.
[55]付月箫等.消脂护肝汤治疗酒精性肝损伤93例临床研究[J].新中医,2007,39(11):72.
[56]郭晓萍,程宇甫.加味四逆散治疗酒精性肝损伤临床研究[J].中国中医药信息杂志,2006,13(6):13.
[57]苗士奎等.脂肝康胶囊治疗酒精性肝损伤的研究[J].中西医结合肝病杂志,2005,15(5):266.
[58]喻洪伟,张春梅.酒肝乐治疗酒精性肝损伤疗效观察[J].辽宁中医杂志,2003,30(14):284.
[59]倪力强,周学文.卷苦肝泰治疗酒精性肝损伤得临床研究[J].辽宁中医杂志,2003,30(5):343.
[60]王芳.清肝解毒汤治疗酒精性肝损伤r-GT升高的体会[J].浙江中医学院学报,2001,25(2):40.
[61]任延明,任世存等.八味护肝胶囊治疗酒精性肝损伤42例临床观察[J].江苏中医药,2004,25(9):25。
[62]沙美,丁林生.枳椇子的化学成分研究.中国药科大学学报 2001,32(6):418-420。
[63]嵇扬,李俊,杨平.枳椇子对急性酒清中毒的作用[J].中药材,2001,24(2):126-128。
[64][英]HaseK...和汉医药学杂志[J].1997,14(1):28-33
[65]嵇扬,杨平,李俊.枳椇子酒与枳棋子水提取液解酒毒作用比较研究[J].时珍国医国药,2001,12(6):481-483
[66]Yoshikawa M,Murakami T,Ueda T,et al.Bioactive constituents of Chinesenatural medicines Ⅱ Absolite stereostructures of new di-hydroflavonols,hoveninitins Ⅰ,ⅡandⅢ,isolated from hoveniae semen fructu,the seed and fruid of Hoveniadulcis THUNB.(Rhamnaceae):inhibitory effect on alcohol-induced muscure laxation and hepatoprotective activity[J].Yakugaku Zasshi,1997,117
[67]张洁、刘庆生等。三七对酒精性肝病防治作用的研究[J]。医学研究杂志,2008;37(3):35-36.
[68]范列英,孔涛,高峰,等.汉防己甲素对成纤维细胞、肝细胞DNA及胶原合成的影响[J].临床肝胆病杂志,1995;11(1):25-26.
[69]刘玉兰,李定国,陆汉明,等.汉防己甲素对肝细胞及成纤维细胞的影响[J].中西医结合肝病杂志,1994;4(4):21-23.
[70]李定国,刘玉兰,陆汉明,等.汉防己甲素对肝纤维化大鼠线粒体的影响[J].中华消化杂志.1994;16(4):339.
[71]王志荣,李定国,魏红山,等.粉防己碱抑制肝纤维化大鼠肝组织c-fos 和c-junmRNA表达[J].上海医学,2003;26(5):332-334.
[72]靖大道,邱德凯,萧树东,等.虫草多糖(CP)对大鼠肝细胞增殖及胶原基因表达的影响[J].肝脏,1999;4(4):215-216.
[73]朱家璇.冬虫夏草对实验性免疫损伤性肝纤维化的预防和治疗作用研究.中华消化杂志,1994;14(6):333.
[74]邱德凯,李海,曾民德,等.虫草多糖对大鼠肝纤维化胶原酶mRNA变化的 影响[J].新消化学杂志,1997;5(7):417-419.
[75]薛惠明,胡义杨,顾宏图,等.丹参抗CC14及DMN诱导的大鼠肝纤维化的研究[J].中西医结合肝病杂志,1999;9(4):16-17.
[76]马学惠,等.丹参对实验性肝硬化细胞外基质影响的免疫组化观察[J].肝脏病杂志,1994;2(2):79.
[77]王晓玲,刘平,刘成海,等.丹酚酸A对成纤维细胞活力增殖及胶原合成的影响[J].中西医结合肝病杂志,2000;10(1):24-25.
[78]刘丽,姜慧卿,张晓凤.丹参单体IH764-3对H2O2刺激肝星状细胞增殖和胶原合成的影响及其机制[J].中国应用生理学杂志,2003;19(1):78-81.
[79]甘乐文,等.氧化苦参碱对大鼠肝纤维化的影响第二军医大学学报,1999,20(7):445-448.
[80]林明华,马迎军,孟庆援,等.苦参素对肝星状细胞增殖及Ⅰ型胶原合成的影响.黑龙江医药科学,2003,26(1):27-28.
[81]康文臻.苦参素对实验性大鼠肝纤维化防治作用的研究[J].世界华人消化杂志,2003;11(2):195-198.
[82]张珉.黄颜木素对HSC-T6细胞增殖和胶原合成的影晌.第二军医大学学报,1999,20(5):304-305.
[83]夏玉涛,卫新革,陈颖伟,等.大黄素对肝纤维化大鼠血清透明质酸的影响[J].中西医结合肝病杂志,1999,9(4):27.
[84]张霄翔,扬雁,陈敏珠.黄芪多糖对HSC-T6细胞增殖及胶原产生的影响[J].中国临床药理学与治疗学,2003;8(6):645-647.
[85]吴强,杨雁,薛绍礼,等.黄芪总甙对肝星状细胞增殖和合成胶原的抑制作用[J].中国药理学通报,2003;19(8):892-895.
[86]胡梅雪.活血化瘀法治疗肝纤维化[J].中医药学报,1998;5(2):13.
[87]赵治友,何永生.慢性肝炎从瘀论治探析[J].中医药学报,1998;5(6):15.
[88]徐萃华,李燕娜.赤芍对体外培养肝细胞(甲基-3H)胸腺嘧啶核苷掺入的影响[J].山西医药杂志,1986;(5):299-232.
[89]李绥军,林玲,王莉.活血清肝汤配合易善复治疗酒精性肝炎45例.陕西中医,2005;26;(1):7-9.
[90]涂立德.硫普罗宁、复方丹参治疗酒精性肝炎40例.赣南医学院学报,2007;27(3):419-420.
[91]阎振文.中西医结合治疗酒精性肝炎30例.中国民间疗法,2007,15(4):4-5.
[92]张洁玉.调肝活血方抗酒精性肝病的临床观察.中医药学报,2007;35(3):56-57.
[1].中华医学会肝病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊标准.中华肝脏病杂志,2003,112):72.
[2].Donofrio G,Bernstein E,Bernatein J,Woolare RH,Brewer PA,Craig SA,Zink BJ,Patients with alcohol problems in the emergency department part1:improving dection.SAEM substance Abuse Task Force.Society for Academeic Emergency Medicine.Acad Emerg Med,1998,5:1200-1209.
[3].Sussman S,Denl VW,Skara S,de Calice P,Tsukamoto H.Alcoholic liver disease(ALD):a new domain for prevention efforts.Subst Use Misuse,2002,37:1887-1904.
[4].Ramstendt M.Alocohol related mortanty in 15 European countries in the post war period,http://www-les-lundis,ined fr/cextes/MatsRamstedt.pdf.
[5].Neuberger J,SchulzKH,DayC,Fleig W,BerlakovichGA,Berenguer M,Pageaux GP,Luccy M,Horsmans Y,Burroughs A,Hockeratedt K.Transplantation for alcoholic liver disease.J Hepatol,2002,36:130-137.
[6].王宝恩,尹珊珊.酒精性肝病的流行病学.中华肝脏病杂志[J],2001;9:312.
[7].凌奇荷,卿笃信.重视对酒精性肝病的研究[J].中华消化杂志,2001,21:517-518.
[8].厉有名,陈卫星,虞朝辉,等.浙江省酒精性肝病流行病学调查概况[J].中华肝脏病杂志,2003,11 11):647-649.
[9].王宏平.88例酒精性肝病的临床分析[J].中外健康文摘·医药学刊,2008,5(1):7-8.
[10].王国祥,王炳元,刘春荣.肝胃乙醇脱氢酶活性与酒精性肝病方式的关系[J].中华肝脏病杂志,2001,9(5):265-267.
[11].Bode CH,Bode,JC.Effect of a;coho;consumption on the gut.Best Practice & Reseach Clinical Gastroenterology,2003,17:574-592.
[12].Niemela O.Distribution of ethanol-induced protain in vivo:relationship to tissue injury in CD14-difcient mice.J Immunol,2001,31:1533-1538.
[13].黄梅芳,酒精性肝病的发病机制的研究进展[J],医学新知杂志 2003,13(2):104-108。
[14].周俊英.缺氧诱导因子-1与酒精性肝病[J].国际内科学杂志.2008;35(9):544-545.
[15].Gordon H.Detection of alcoholic liver disease.World J Gastroencerol,2001,7:297-302.
[16].Bellentani S,Saccoecio G,Costa G,Tiribelli C,Manenti F,Sodde M,Saveria Croce L,Sasso F,Pozzato G,Cristianini G,Brandi G.Drinking habits as cofactors of risk for alcohol induced liver damage.The Dionysos Study Group.Gut,1997,41:845-850.
[17].鲁晓岚,陶明,罗金燕等.饮酒与肝病流行病学调查[J].中华肝脏病杂志,2002,10:467-468.
[18].Morgan MY,Sherlock S.Sxe-related differences among 100 patients with alcoholicliver disease.Br Med J,1977;5:1939-1941.
[19].Casini A.Acetaldehyde induces clos and cjun drotooncogenes in fat-storing cellcultures through protein kinase C activation.Alcohol,1994;29:303-313
[20].Westin J,Lagging LM,Spak F,Aires N,Svensson E,Lindh M,Dhillon AP,Norkrans G,WejstalR.Moderatoalcoholinstake increasesfibrosisprogression in untreated pationts with hepatitis C virus infection.J Viral Hepat,2002,9:235-241.
[21].Bunout D.Nutritional and metabolic effects of alcoholism:their relationship with alcoholic liver disease.Nutrition.1999,15:583-589.
[22].中华医学会肝病学分会脂肪肝和酒精性肝病学组,酒精性脂肪性肝病诊断标准[J],中华肝脏病杂志2006,3,14,3.164-166.
[23].中华医学会肝病学分会脂肪肝和酒精性肝病学组,酒精性脂肪肝性肝病诊断标准[J],中华肝脏病杂志 2003,11:72.
[24].Sanyal AJ.AGA technical review on nonalcoholic fatty liver disease.Gastroenterology 2002;123:1705-1725.
[25].Graif M,Yanuka M,Baraz M,et al.Quantitative estimation of attenuation in ultrasound video images:correlation with histology in diffuse liver disease.Invest Radiol 2000;35:319-324.
[26].Ataseven H,Yildrim MH,Yalniz M,et al.Correlation between computerized tomographic findings and histopathologic grade/stage innon-alcoholic steatohepatitis.J Hepatol 2003;38(Suppl 2):A4177.
[27].Farrell GC,George J,Pauline MH,McCullough AJ,eds.Fatty liver diseas:NASH and related disorders.Oxford:Blackwell Publishing 2005:159-207.
[28].桂红莲,谢青.肝纤维化无创性诊断的研究进展.内科理论与实践[J], 2007,2(25):360-363.周新,涂植光.临床生物化学和生物化学检验.人民卫生出版社.2003,167-168.
[29].周新,涂植光.临床生物化学和生物化学检验[J].人民卫生出版社.2003,167-168.
[30].叶彬,潘发愤.酒精性脂肪肝和肝硬化患者各种血清酶的检测及其临床评价[J].浙江临床医学,2006,8(12):1252-1253.
[31].詹雨林,李国航,骆欢.慢性肝病血清γ-谷氨酰转移转酶测定的临床意义[J].中国实用医药,2007,2 25):42-43.
[32].朱一堂,孙艳,李福坤,等.血清亮氨酸氨基肽酶和γ-谷氨酰转肽酶在酒精性肝病诊断中的应用[J].国际检验医学杂志,2006,2712):1146-1147.
[33].陆伦根.肝纤维化非创伤性诊断的临床应用[J].中华肝脏病杂志,2007,15:777-778.
[34].孟繁坤,丁蕾,郑颖,等.超声判别慢性肝病肝纤维化分期与病理背离问题探讨[J].临床超声医学杂志,2007,9:394-397.
[35].孟繁坤,郑颖,葛辉玉,等.高频超声检查与病理肝纤维化分期相关性的半定量研究[J].中国超声医学杂志,2007,23(11):846-848.
[36].McCullough AJ,O′ Connor JF.Alcoholic liver disease:proposed recommendations for the American College of Gastroenterology.Am J Gastroenterol 1998;93:2022-2036.
[37].Sticke1 F,Roehn B,Schuppan D,et at.Review article:Nutritional therapy in alcoholic liver disease.Aliment Pharmacol Ther 2003;18:357-373.
[38].Mathurin P,Mendenhall CL,Carithers RL Jr,et al.Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis(AH):individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH.JHepatol 2002;36:480-487.
[39].Imperiale TF,O′Connor JB,McCullough AJ.Corticosteroids are effective in patients with severe alcoholic hepatitis.Am J Gastroenterol 1999;94:3066-3068.
[40].Shpilenya LS,Muzychenko AP,Gasbarrini G,et al.Metadoxine in acute alcohol intoxication:a double-blind,randomized,place bocontrolled study.Alcohol Clin Exp Res 2002;26:340-346.
[41].Medina J,Moreno-Otero R.Pathophysiological basis for antioxidant therapy in chronic liver disease.Drugs 2005;65:2445-2461.
[42].胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏2005;10:5-7.
[43].Lieber CS,Leo MA,Cao Q,et al.Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons.J Clin Gastroenterol 2003;37:336-339.
[44].Murray KF,Carithers RL Jr;AASLD.AASLD practice guidelines Evaluation of t the patient for liver transplantation.Hepatology 2005;41:1407-1432.
[45].黄飚.23例酒精性肝硬化诊治分析.医学理论与实践[J],2008,21(6):679-680.
[46].Stickel F,Hoehn B,Schuppan D,et al.Review article:Nutritional therapy in alcoholic liver disease.Aliment Pharmacol Ther 2003;18:357-373.
[47].MendenhallCL,ToschT,WeesnerRE,etal.Vacooperative study on Alcoholic hepatitis.Ⅱ.Prognostic significance of protein 2calorie malnutrition[J].Am J Clin Nutr,1986;43:213-221.
[48].Rambaldi A,Gluud C.Anabolic-androgenic steroids for alcoholic liverdisease[J].Cochrane Database Syst Rev,2006,(4):CD003045.
[49].王宛明,王道存.多烯磷脂酰胆碱治疗酒精性肝病疗效观察[J].现代中西医结合杂志.2008,17(25):3941-3942.
[50].Lieber CS.New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments[J].Curr Gastroenterol Rep,2004,6:60-65.
[51].Lieber CS.Liver diseases by alcohol and hepatitis C:early detection and new insights in pathogenesis lead to improved treatment[J].Am J Addict,2001,10(Suppl):29-50.
[52].Mookerjee Rp,Tilg H,Williams R,etal.Infliximab and alcoholic hepatitis[J].Hepatology,2004,40:499-500.
[53].万远太.酒精性肝病的药物治疗现状[J].武汉科技大学学报(自然科学版),2006,29(2):194-196.
[54].范建高,曾民德.脂肪性肝病[M].北京:人民卫生出版社,2005:366-410.。
[3]Levitsky J,Mailliard ME.D iagnosis and therapy of alcoholic liv2er disease[J].Sem in Liver D is,2004,24:233-247.
[55].Neuber ger J,Schulz KH,Day C,etal.Transplantation for alcoholic liver disease[J].Hepatol,2002;36:130-137.
[56].Friedman SL.Liver fibrosis-fran bench to beside.J.J Hepatology,2003,38:S38-S53.
[1]庄辉.酒精性肝病的流行病学[J].中华肝脏病杂志,2003;11(11):689
[2]O' Keefee C,McCormick PA.Severe acute alcoholic hepatitis:an audit of medical treatment.Ir Med J 2002;95:108-109
[3]Campollo O,,Martinez MD,Valencia JJ,Segura-Ortega J.Drinking patterns and beverage preferences of liver cirrhosis patients in Mexico.Subst Use Misuse 2001;36:387-398
[5]Bopp M,Gmel G.Alcohol consumption and gender in the 20th century:the case of Switzerland.Soz Praventivmed 1999;44:211-221
[4]Campollo O,Martinez MD,Valencia JJ,Segura-Ortega J.Drinking patterns and beverage preferences of liver cirrhosis patients in Mexico.Subst Use Misuse 2001;36:387-398
[5]江正辉,王泰龄.酒精性肝病[J],中国医药科技出版社,2001;116
[6]Campollo O,,Martinez MD,Valencia JJ,Segura-Ortega J.Drinking patterns and beverage preferences of liver cirrhosis patients in Mexico.Subst Use Misuse 2001;36:387-398
[7]酒精性肝病诊断标准(草案)[J].中华肝脏病杂志,2001,9(5):264
[8]Cotton NS.The familial incidence of alcoholism:a review.J Stud Alcohol 1979;40:89-116
[9]Gordon H.Detection of alcoholic liver disease.World J Gastroenterol 2001,7:297-302。
[10]陈卫星.酒精性肝病流行病学调查和危险因素分析[J].博士论文.2001,5(1):15-16
[11]Gordon H.Detection of alcoholic liver disease.World J Gastroenterol 2001:7:297-302
[12]Grant BF,Noble J,Malin H.Dcclinein liver irrhosis mortality and components of change:United States,1973-1983.AIcohol Health and Research World,1980,10:66-75
[13]Sorbi D,Boynton J,Lindor KD.The ratio of aspartate aminotransferase toalanine aminotransferase potential value in differentiating nonalcoholicsteatohepatitis from alocoholic liver disease.Am J Gastroenterol,1999,94:1018-1022
[14]张道明,王远新,赵洪川,等.酒精性肝病-附136例临床与病理[J].胃肠病学和肝病学杂志.1996,5(3):196-201
[1]袁世宏,张连文,王米渠.数理统计思想及方法在辨证规范化研究中的应用及思考.中国中医基础医学杂志,2003;9(4):15-19。
[2]陈平雁,黄淅明.SPSS10.0统计软件应用教程.人民军医出版社,2002:198-199.